Legend Biotech (LEGN) Income towards Parent Company (2019 - 2025)
Legend Biotech (LEGN) posted Income towards Parent Company of -$30.9 million for Q4 2025, up 19.65% on a QoQ basis from -$38.5 million in Q3 2025, and down 117662.01% year-over-year from N/an in Q4 2024.
Legend Biotech (LEGN) Income towards Parent Company (2019 - 2025) Analysis & Trends
Legend Biotech's Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$30.9 million for Q4 2025.
- Quarterly Income towards Parent Company fell 117662.01% year-over-year to -$30.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$294.5 million (down 44.87% YoY) and the FY2025 annual result came in at -$296.8 million, down 167558.99% from the prior year.
- Income towards Parent Company was -$30.9 million for Q4 2025 at Legend Biotech, up from -$38.5 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $172.6 million in Q2 2021 and bottomed at -$199.1 million in Q2 2023.
- A 5-year average of -$67.9 million and a median of -$73.6 million in 2022 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2021 — Income towards Parent Company surged 227.95% — and 2025, when it tumbled 117662.01%.
- Legend Biotech's Income towards Parent Company stood at -$88.3 million in 2021, then tumbled by 53.82% to -$135.9 million in 2022, then jumped by 99.89% to -$144818.0 in 2023, then soared by 118.15% to $26284.0 in 2024, then tumbled by 117662.01% to -$30.9 million in 2025.
- Business Quant data shows LEGN's Income towards Parent Company at -$30.9 million in Q4 2025, -$38.5 million in Q3 2025, and -$124.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Legend Biotech | 8.26 Bn | 7.36 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -30.90 Mn |
| Sep 30, 2025 | -38.46 Mn |
| Jun 30, 2025 | -124.22 Mn |
| Mar 31, 2025 | -100.92 Mn |
| Dec 31, 2024 | 26,284.00 |
| Sep 30, 2024 | -125.32 Mn |
| Jun 30, 2024 | -18.20 Mn |
| Mar 31, 2024 | -59.79 Mn |
| Dec 31, 2023 | -144,818.00 |
| Sep 30, 2023 | -62.21 Mn |
| Jun 30, 2023 | -199.13 Mn |
| Mar 31, 2023 | -112.10 Mn |
| Dec 31, 2022 | -135.88 Mn |
| Sep 30, 2022 | -84.96 Mn |
| Jun 30, 2022 | -193.23 Mn |
| Mar 31, 2022 | -32.29 Mn |
| Dec 31, 2021 | -88.33 Mn |
| Sep 30, 2021 | -124.75 Mn |
| Jun 30, 2021 | 172.57 Mn |
| Mar 31, 2021 | -90,521.00 |